Reports Q4 revenue $$227.00M, consensus $140.95M.”With the recent launch of our first independent medicine, TRYNGOLZA for familial ...
The biotech industry is ripe with great investment opportunities due to technological advancements such as artificial ...
“We recognize that those with rare diseases often have complex needs that go unmet by traditional assistance,” said Green.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest ...
CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...